These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1850 related articles for article (PubMed ID: 25923331)

  • 1. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichostatin A augments esophageal squamous cell carcinoma cells migration by inducing acetylation of RelA at K310 leading epithelia-mesenchymal transition.
    Huang K; Liu Y; Gu C; Liu D; Zhao B
    Anticancer Drugs; 2020 Jul; 31(6):567-574. PubMed ID: 32282366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.
    Ahrens TD; Timme S; Ostendorp J; Bogatyreva L; Hoeppner J; Hopt UT; Hauschke D; Werner M; Lassmann S
    Lab Invest; 2016 Mar; 96(3):307-16. PubMed ID: 26692290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
    El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
    Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines.
    Ma J; Guo X; Zhang S; Liu H; Lu J; Dong Z; Liu K; Ming L
    Mol Med Rep; 2015 Jun; 11(6):4525-31. PubMed ID: 25634603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
    Yuan J; Llamas Luceño N; Sander B; Golas MM
    Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma.
    Meng Y; Wang QG; Wang JX; Zhu ST; Jiao Y; Li P; Zhang ST
    Dig Dis Sci; 2011 Nov; 56(11):3195-203. PubMed ID: 21567192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway.
    Liu D; Liu Y; Qi B; Gu C; Huo S; Zhao B
    Cancer Med; 2021 Aug; 10(15):5235-5245. PubMed ID: 34160902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
    Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.